Over the past decade, therapeutic options in multiple myeloma (MM) have changed dramatically. Given the unprecedented efficacy of novel agents, the role of hematopoietic cell transplantation (HCT) in MM remains under scrutiny. Rapid advances in myeloma immunotherapy including the recent approval of chimeric antigen receptor (CAR) T-cell therapy will impact the MM therapeutic landscape. The…
The number of long-term survivors of hematopoietic cell transplantation (HCT) and cellular therapy is rapidly expanding. Guidelines for the screening and preventative practices for HCT…
On April 10, 2024, the Centers for Medicare & Medicaid Services (CMS) issued the fiscal year (FY) 2025 Medicare hospital inpatient prospective payment system (IPPS)…
This webinar is the first in a series of three presented by the ASTCT Palliative Care SIG. The speakers will share their insight as to…
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,600 physicians, investigators and other health care professionals…
The Food and Drug Administration approves CAR T-Cell therapy Abecma as a second-line treatment and the CAR T-Cell therapy Carvykti as a third-line treatment for…
The number of long-term survivors of hematopoietic cell transplantation (HCT) and cellular therapy is rapidly expanding. Guidelines for the screening and preventative practices for HCT…
This webinar is the first in a series of three presented by the ASTCT Palliative Care SIG. The speakers will share their insight as to…
The Food and Drug Administration approves CAR T-Cell therapy Abecma as a second-line treatment and the CAR T-Cell therapy Carvykti as a third-line treatment for…
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,600 physicians, investigators and other health care professionals…
